Experimental vaccine targets HPV-16 tumors in early trial

NCT ID NCT07081984

Recruiting now Disease control Sponsor: Therorna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new therapeutic vaccine called TI-0093 in 12 adults with HPV-16 positive cancers that have returned or spread. The vaccine is given as a series of five shots over about a month. The main goals are to check safety, find the best dose, and see if the vaccine triggers an immune response against the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TI-0093 injection (therapeutic tumor vaccine)
What this could lead to: If it works, this could point toward a new treatment option for people with HPV-16 related cancers that have come back or spread.
What could go wrong: This is a very early, small Phase 1 trial with only 12 participants, focused mainly on safety and dosing. It may not show strong anti-tumor effects, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma head and neck squamous cell carcinoma Neoplasm Metastasis Squamous Cell Carcinoma of Head and Neck Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER HNSCC HPV 16+ RECURRENT OR METASTATIC CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.